Published in Diabetes on December 10, 2008
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia (2011) 1.76
Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes (2010) 0.92
Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res (2011) 0.91
Altered proportions of naïve, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes. J Clin Immunol (2011) 0.90
Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc Diabetol (2014) 0.87
Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials. Diabetol Metab Syndr (2009) 0.86
Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Clin Exp Immunol (2013) 0.83
Effects of genetic susceptibility for type 2 diabetes on the evolution of glucose homeostasis traits before and after diabetes diagnosis: data from the D.E.S.I.R. Study. Diabetes (2011) 0.83
Year in review 2013: Critical Care--metabolism. Crit Care (2014) 0.82
Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective study. Crit Care (2013) 0.82
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass. Diabetes Metab J (2016) 0.79
Exenatide pretreatment improved graft function in nonhuman primate islet recipients compared to treatment after transplant only. J Transplant (2012) 0.79
Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice. PLoS One (2014) 0.78
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. Korean J Intern Med (2015) 0.77
Use of glucagon-like peptide-1 agonists to improve islet graft performance. Curr Diab Rep (2013) 0.77
Discovery of gastric inhibitory polypeptide and its subsequent fate: Personal reflections. J Diabetes Investig (2016) 0.75
Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update. J Diabetes Res (2015) 0.75
Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol Diabetes Metab Case Rep (2016) 0.75
Stem cell therapy for diabetes mellitus. Kidney Int Suppl (2011) (2011) 0.75
Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8+T Effector Memory Subset. PLoS One (2015) 0.75
Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice. Front Pharmacol (2017) 0.75
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell (1992) 28.36
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med (2000) 18.26
Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care (2006) 4.91
Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol (1994) 4.65
The role of gut hormones in glucose homeostasis. J Clin Invest (2007) 3.36
Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol (2006) 3.31
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab (2006) 3.28
A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A (2000) 3.28
Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci (2004) 3.27
Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science (1990) 3.17
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 3.17
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem (1993) 2.93
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology (2004) 2.65
Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol (2004) 2.40
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
CD26, let it cut or cut it down. Immunol Today (1999) 2.24
Performance measurement of the microPET focus 120 scanner. J Nucl Med (2007) 2.10
Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract (2007) 2.04
Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A (2007) 1.71
Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells. J Biol Chem (2001) 1.60
Islet filtration: a simple and rapid new purification procedure that avoids ficoll and improves islet mass and function. Transplantation (2002) 1.58
Quantification of target gene expression by imaging reporter gene expression in living animals. Nat Med (2000) 1.56
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A (2007) 1.43
Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes (1995) 1.42
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 1.37
Spatial regulation of the cAMP-dependent protein kinase during chemotactic cell migration. Proc Natl Acad Sci U S A (2005) 1.32
Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol (2007) 1.24
Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J Biol Chem (2007) 1.20
Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology (2007) 1.20
Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology (2003) 1.13
Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia (2007) 1.12
MHC class II deprivation impairs CD4 T cell motility and responsiveness to antigen-bearing dendritic cells in vivo. Proc Natl Acad Sci U S A (2007) 1.11
Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med (2006) 1.10
Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes (2008) 1.10
Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol (2002) 0.98
A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis. J Biol Chem (2005) 0.90
Rapid and reproducible radiosynthesis of [18F] FHBG. Nucl Med Biol (2004) 0.86
Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept (2005) 0.85
Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation (1997) 0.85
Islet transplant: an option for childhood diabetes? Arch Dis Child (2003) 0.84
Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme. Biol Chem (2003) 0.82
Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. Adv Exp Med Biol (2003) 0.82
Ischemia/reperfusion injury: The role of CD26/dipeptidyl-peptidase-IV-inhibition in lung transplantation. Transplant Proc (2006) 0.81
[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem (2003) 0.80
CD26/DPP IV in experimental and clinical organ transplantation. Adv Exp Med Biol (2003) 0.79
Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol (2003) 0.78
Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet (2009) 2.29
Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun (2002) 2.28
SOX4 cooperates with neurogenin 3 to regulate endocrine pancreas formation in mouse models. Diabetologia (2015) 1.40
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 1.37
Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol (2007) 1.24
Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem (2007) 1.21
Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun (2007) 1.17
Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology (2003) 1.13
Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta (2005) 1.12
Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem (2002) 1.12
Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med (2006) 1.10
Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes (2008) 1.10
Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem (2007) 1.09
Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am J Physiol Endocrinol Metab (2003) 1.09
Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography. J Cereb Blood Flow Metab (2002) 1.07
Intracerebroventricular corticotropin-releasing factor increases limbic glucose metabolism and has social context-dependent behavioral effects in nonhuman primates. Proc Natl Acad Sci U S A (2002) 1.03
Imaging of enzyme replacement therapy using PET. Proc Natl Acad Sci U S A (2010) 1.03
Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem (2009) 1.03
A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One (2010) 1.02
Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab (2002) 1.01
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J Biol Chem (2009) 1.01
A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J (2002) 1.01
Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab (2011) 0.99
GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res (2010) 0.99
Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology (2010) 0.95
Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes (2010) 0.92
Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes (2002) 0.92
Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease. J Neuropathol Exp Neurol (2007) 0.92
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes (2002) 0.91
In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cereb Blood Flow Metab (2002) 0.91
Pancreatic beta-cell overexpression of the glucagon receptor gene results in enhanced beta-cell function and mass. Am J Physiol Endocrinol Metab (2009) 0.91
A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis. J Biol Chem (2005) 0.90
Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease. J Neuropathol Exp Neurol (2007) 0.88
Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization. PLoS One (2012) 0.88
Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem (2009) 0.88
In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab (2007) 0.86
Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci (2007) 0.86
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging (2010) 0.85
Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol (2006) 0.85
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. J Neurochem (2012) 0.85
Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F]setoperone. Biol Psychiatry (2005) 0.85
In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sci (2004) 0.84
Structure-function analysis of a series of novel GIP analogues containing different helical length linkers. Biochemistry (2003) 0.84
Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation. J Lipid Res (2011) 0.84
Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care (2003) 0.84
Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA. Front Biosci (2004) 0.82
Glucose-dependent insulinotropic polypeptide (GIP): development of DP IV-resistant analogues with therapeutic potential. Adv Exp Med Biol (2003) 0.82
Amphetamine challenge decreases yohimbine binding to α2 adrenoceptors in Landrace pig brain. Psychopharmacology (Berl) (2012) 0.81
Incretin-stimulated interaction between β-cell Kv1.5 and Kvβ2 channel proteins involves acetylation/deacetylation by CBP/SirT1. Biochem J (2013) 0.81
GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One (2012) 0.81
Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol Imaging Biol (2007) 0.81
Npas4 is a novel activity-regulated cytoprotective factor in pancreatic β-cells. Diabetes (2013) 0.81
Positron emission tomography receptor assay with multiple ligand concentrations: an equilibrium approach. Methods Enzymol (2004) 0.81
[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo. J Biol Chem (2003) 0.80
Quantitative in vitro phosphor imaging using [3H] and [18F] radioligands: the effects of chronic desipramine treatment on serotonin 5-HT2 receptors. J Neurosci Methods (2005) 0.80
Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. Neuroimage (2004) 0.79
The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study. Phys Med Biol (2005) 0.79
Pathological gambling: relation of skin conductance response to dopaminergic neurotransmission and sensation-seeking. Eur Neuropsychopharmacol (2010) 0.78
Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry. Exp Neurol (2013) 0.78
Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol (2003) 0.78
Resistin knockout mice exhibit impaired adipocyte glucose-dependent insulinotropic polypeptide receptor (GIPR) expression. Diabetes (2012) 0.77
Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP). Biol Chem (2003) 0.77
Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet (2015) 0.77
How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease? Curr Neurol Neurosci Rep (2015) 0.77
Rett syndrome: investigation of nine patients, including PET scan. Can J Neurol Sci (2002) 0.76
On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. Diabetes Care (2002) 0.76
Effects of anesthesia and species on the uptake or binding of radioligands in vivo in the Göttingen minipig. Biomed Res Int (2013) 0.75
Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective". Biochem Biophys Res Commun (2002) 0.75
Relative contribution of incretins to the glucose lowering effect of DP IV inhibitors in type 2 diabetes mellitus (T2DM). Adv Exp Med Biol (2006) 0.75
Functional neuroimaging in Parkinson's disease. Expert Opin Med Diagn (2011) 0.75
Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates. Neurodegener Dis (2012) 0.75